ChronTech receives extended offer from a group of shareholder

As earlier has been communicated an extra general meeting (EGM) in ChronTech
Pharma AB (the Company) on the 19th of April 2013 resolved to accept that a
group of shareholders acquire a percentage of approximately 70 per cent of the
Company’s projects regarding development of DNA vaccines against hepatitis B and
hepatitis C.

The group of shareholders has now offered to acquire the entire, i.e. also the
remainder 30% and not only approximately 70% of the Company’s project regarding
development of DNA vaccines against hepatitis B and hepatitis C. The purchase
consideration now also includes a deferred consideration of 1 MUSD. The proposal
also includes the funding of the development of the IVIN DEVICE for use in
combination with hepatitis vaccines up to US$1,500,000 on the development of the
IVIN DEVICE in exchange for an exclusive license for use with hepatitis
vaccines. Please see attached “term sheet”. This ”term sheet” will be available
on the Company’s website.

An EGM will be summoned to let the shareholders decide about the above.
Shareholders representing more than 60 per cent of the shares in the Company
have declared that they will support this new proposal for the reconstruction of
the Company.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@chrontech.se

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs
against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic
infections with jaundice causing viruses which can lead to liver cirrhosis and
liver cancer. ChronTech has also developed and further develops a patent pending
new type of injection needle for a more effective uptake of DNA vaccines.
ChronTech also have part ownership in the wound healing therapy ChronSeal®, and
in the new platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium Nordic AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.